These conclusions support the idea that treating PCa patients with a combination of IDO inhibitors (indoximod), anti-CTLA-4 mAb, and DC-based vaccinations (Provenge) may be a successful course of action [47]. The gene discussed is CTLA4; the disease is posterior cortical atrophy.